updated 2/1/2011 10:19:27 AM ET 2011-02-01T15:19:27

DALLAS, Feb. 1, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Orexigen Therapeutics Inc. (Nasdaq:OREX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/OREX

Orexigen Therapeutics Inc. (OREX) is a biopharmaceutical company focused on the treatment of obesity. Its lead product candidates reflect a growing understanding of how the central nervous system (CNS) regulates appetite and metabolism as well as the mechanisms that limit weight loss over time. OREX's lead combination product candidates targeted for obesity are Contrave, which has completed Phase III clinical trials and has submitted a New Drug Application (NDA) for FDA review, and Empatic, which has completed Phase II clinical development.

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"OREX shares took a nosedive this morning, dropping more than 70% in pre-market trading on news that the FDA has rejected the company's weight loss drug Contrave. The FDA instructed the company to conduct new clinical trials to demonstrate the long-term, cardiac safety of Contrave, rejecting the drug despite recommendation by an outside advisory committee that in December voted Contrave approvable."

"The news comes as a blow to the company who was vying to be the first company to receive FDA approval for a new weight loss drug in year 2011. OREX now joins the bench with Arena Pharmaceuticals (Nasdaq:ARNA) and Vivus Inc. (Nasdaq:VVUS), whose diet pills were also rejected by the FDA."

To read the entire report visit: www.microstockprofit.com/lp/OREX

See what investors are saying about OREX at http://www.stockhideout.com

Get breaking news on OREX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com